This company listing is no longer active
B1N Stock Overview
A clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Neuphoria Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.007 |
| 52 Week High | US$0.04 |
| 52 Week Low | US$0.0024 |
| Beta | 1.75 |
| 1 Month Change | 191.67% |
| 3 Month Change | 25.00% |
| 1 Year Change | -76.67% |
| 3 Year Change | -94.17% |
| 5 Year Change | -97.67% |
| Change since IPO | -91.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| B1N | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 4.0% | 0.7% |
| 1Y | -76.7% | -10.2% | 8.4% |
Return vs Industry: B1N underperformed the German Biotechs industry which returned -3.1% over the past year.
Return vs Market: B1N underperformed the German Market which returned 12.1% over the past year.
Price Volatility
| B1N volatility | |
|---|---|
| B1N Average Weekly Movement | 83.0% |
| Biotechs Industry Average Movement | 7.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 12.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: B1N's share price has been volatile over the past 3 months.
Volatility Over Time: B1N's weekly volatility has increased from 59% to 83% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | n/a | Spyros Papapetropoulos | www.bionomics.com.au |
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company’s lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.
Neuphoria Therapeutics Inc. Fundamentals Summary
| B1N fundamental statistics | |
|---|---|
| Market cap | €6.40m |
| Earnings (TTM) | -€14.88m |
| Revenue (TTM) | €3.59m |
1.8x
P/S Ratio-0.4x
P/E RatioIs B1N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| B1N income statement (TTM) | |
|---|---|
| Revenue | AU$6.02m |
| Cost of Revenue | AU$19.80m |
| Gross Profit | -AU$13.79m |
| Other Expenses | AU$11.13m |
| Earnings | -AU$24.91m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.017 |
| Gross Margin | -229.04% |
| Net Profit Margin | -413.94% |
| Debt/Equity Ratio | 0% |
How did B1N perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/09/01 14:46 |
| End of Day Share Price | 2023/08/24 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Neuphoria Therapeutics Inc. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tanushree Jain | Bell Potter |
| Esther Lannie Hong | Berenberg |
| Charles Duncan | Cantor Fitzgerald & Co. |